Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | LGMN | Q99538 | 2/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18700910 | 0.89 | MAPT (0.58) | MAPTPDK2PDE3BPDE3ALGMN | |
| SCHEMBL31381229 | 0.85 | NOTUM (0.56) | PDK2PTGESHSD17B10NOTUMKDM4E | |
| SCHEMBL3820949 | 0.85 | NOTUM (0.56) | PDK2PTGESHSD17B10NOTUMKDM4E | |
| SCHEMBL18640051 | 0.84 | MAPT (0.55) | MAPTPDK2PDE3BPDE3ALGMN | |
| SCHEMBL31381251 | 0.83 | PDK2 (0.49) | MAPTPDK2LGMNPTGESNOTUM | |
| SCHEMBL20616398 | 0.83 | MAPT (0.54) | MAPTPDK2PDE3BPDE3ALGMN | |
| SCHEMBL3821499 | 0.82 | ACACB (0.46) | MAPTPTGESALDH1A1 | |
| SCHEMBL20065165 | 0.82 | NOTUM (0.48) | MAPTPDK2PDE3BPDE3ASMN1; SMN2 | |
| SCHEMBL13896503 | 0.81 | MAPT (0.66) | MAPTPDK2PDE3BPDE3AMEN1 | |
| SCHEMBL12082135 | 0.80 | MAPT (0.68) | MAPTPDK2PDE3BPDE3ALGMN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314113-B2 | Substituted dihydroquinazolines II | AICURIS GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | disclosed |
| US-8314113-B2 | Substituted dihydroquinazolines II | AICURIS GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | disclosed |
| US-8314113-B2 | Substituted dihydroquinazolines II | AICURIS GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | disclosed |
| EP-1685123-B1 | SUBSTITUTED DIHYDROQUINAZOLINES II | BAYER HEALTHCARE AG (DE) | 2009-08-19 | — | — | EP | disclosed |
| US-20070281953-A1 | Substituted Dihydroquinazolines II | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | US | disclosed |
| US-20070281953-A1 | Substituted Dihydroquinazolines II | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | US | disclosed |
| US-20070281953-A1 | Substituted Dihydroquinazolines II | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281953-A1 | Substituted Dihydroquinazolines II | EIF2AK2, QDPR, IRF3 | MAPT 2707/4885PDK2 197/4885PDE3B 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.